乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究

doi:10.11904/j.issn.1002-3070.2019.02.003

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (2): 110-114.doi: 10.11904/j.issn.1002-3070.2019.02.003

乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究

陈艳波¹, 孔德嘉², 张金锋¹, 马志刚³

1.哈尔滨医科大学附属肿瘤医院乳腺外科一病区(哈尔滨 150081);
2.黑龙江省第二医院;
3.哈尔滨医科大学附属肿瘤医院胃肠道肿瘤内科病区

收稿日期:2019-01-02 修回日期:2019-01-30 出版日期:2019-04-20 发布日期:2019-04-25
通讯作者: 陈艳波,E-mail:cbcs@vip.sina.com
作者简介:陈艳波,男,(1978-),博士,副主任医师,从事乳腺癌基础的研究
基金资助:
黑龙江省教育厅课题(编号:12541340)

Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients

CHEN Yanbo¹, KONG Dejia², ZHANG Jinfeng¹, MA Zhigang³

1.Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China;
2.The Second Hospital of Heilongjiang Province;
3.Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital

Received:2019-01-02 Revised:2019-01-30 Online:2019-04-20 Published:2019-04-25

摘要/Abstract

摘要： 目的探究乳腺癌患者CYP2D6基因多态性与他莫昔芬药物代谢产物浓度之间的关系。方法收集2010年1月—2012年12月我院乳腺癌患者的外周血样本,检测CYP2D6基因上rs16947,rs1065852和rs28371725三种单核苷酸多态性(Single nucleotide polymorphism,SNP)位点的基因型及他莫昔芬代谢产物在血液中的浓度。应用非参数检验中的独立样本Kruskal-Wallis检验进行统计学分析。结果 CYP2D6基因上rs16947位点不同基因型携带者间他莫昔芬代谢产物4-OH-N-D-TAM和4'OH-N-D-TAM在血液中的浓度具有统计学差异(P=0.049),表明CYP2D6基因上的rs16947位点影响他莫昔芬药物在人体内的代谢。结论乳腺癌患者CYP2D6基因rs16947位点的基因型与部分他莫昔芬代谢产物的血液浓度有关。

关键词: 乳腺癌, CYP2D6, SNP, 他莫昔芬, 代谢产物

Abstract: Objective The objective of this study was to investigate the relationship between CYP2D6 gene polymorphisms and the concentrations of tamoxifen metabolites in breast cancer patients. Methods Peripheral blood samples from breast cancer patients were collected to detect the single nucleotide polymorphism(SNP)of s16947,rs1065852 and rs28371725 gene sites on CYP2D6 gene from January 2010 to December 2012.Genotypes of the three SNPs of CYP2D6 and the concentrations of tamoxifen metabolites were detected in breast cancer patients.Statistical analysis was performed using an independent sample Kruskal-Wallis test in a nonparametric test. Results There was a statistical difference in the concentrations of tamoxifen metabolites 4-OH-N-D-TAM and 4'OH-N-D-TAM in the blood in different CYP2D6 gene genotype carriers at rs16947 site(P=0.049),indicating that the rs16947 site of CYP2D6 gene affected the metabolism of tamoxifen drug in breast cancer patients. Conclusion The genotype of CYP2D6 gene at rs16947 site is related to the blood concentration of tamoxifen metabolites in breast cancer patients.

Key words: Breast cancer, CYP2D6, SNP, Tamoxifen, Metabolism

中图分类号:

R737.9

陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.

CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics[J].CA Cancer J Clin,2018,68(1):7-30.
2 Hinohara K,Wu HJ,Vigneau S,et al.KDM5 Histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance[J].Cancer Cell,2018,34(6):939-953.
3 Early Breast Cancer Trialists' Collaborative G,Davies C,Godwin J,et al.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.
4 Early Breast Cancer Trialists' Collaborative G.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,365(9472):1687-1717.
5 Gao A,Sun T,Ma G,et al.LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERalpha pathway[J].Nat Commun,2018,9(1):4180.
6 Lim YC,Li L,Desta Z,et al.Endoxifen,a secondary metabolite of tamoxifen,and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells[J].J Pharmacol Exp Ther,2006,318(2):503-512.
7 Lien EA,Solheim E,Kvinnsland S,et al.Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile[J].Cancer Research,1988,48(8):2304-2308.
8 Ingle JN,Suman VJ,Johnson PA,et al.Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer[J].Clin Cancer Res,1999,5(7):1642-1649.
9 Broly F,Gaedigk A,Heim M,et al.Debrisoquine/sparteine hydroxylation genotype and phenotype:analysis of common mutations and alleles of CYP2D6 in a European population[J].DNA Cell Biol,1991,10(8):545-558.
10 Madlensky L,Natarajan L,Tchu S,et al.Tamoxifen metabolite concentrations,CYP2D6 genotype,and breast cancer outcomes[J].Clin Pharmacol Ther,2011,89(5):718-725.
11 Chin FW,Chan SC,Abdul Rahman S,et al.CYP2D6 genetic polymorphisms and phenotypes in different ethnicities of malaysian breast cancer patients[J].Breast J,2016,22(1):54-62.
12 Gaedigk A,Simon SD,Pearce RE,et al.The CYP2D6 activity score:translating genotype information into a qualitative measure of phenotype[J].Clin Pharmacol Ther,2008,83(2):234-242.
13 Nowell SA,Ahn J,Rae JM,et al.Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients[J].Breast Cancer Res Treat,2005,91(3):249-258.
14 Lim HS,Ju Lee H,Seok Lee K,et al.Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer[J].J Clin Oncol,2007,25(25):3837-3845.
15 Jin Y,Desta Z,Stearns V,et al.CYP2D6 genotype,antidepressant use,and tamoxifen metabolism during adjuvant breast cancer treatment[J].J Natl Cancer Inst,2005,97(1):30-39.
16 Xu Y,Sun Y,Yao L,et al.Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment[J].Ann Oncol,2008,19(8):1423-1429.
17 Okishiro M,Taguchi T,Jin Kim S,et al.Genetic polymorphisms of CYP2D6 10 and CYP2C19 2,3 are not associated with prognosis,endometrial thickness,or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen[J].Cancer,2009,115(5):952-961.
18 Rae JM,Drury S,Hayes DF,et al.CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients[J].J Natl Cancer Inst,2012,104(6):452-460.
19 Jung JA,Lim HS.Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer:a meta-analysis[J].Pharmacogenomics,2014,15(1):49-60.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[5]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[6]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[7]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[8]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[9]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[10]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[11]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[12]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[13]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.
[14]	李红阳, 孙亮, 姜醒, 苑光军, 刘艳. 蝙蝠葛碱在人乳腺癌MCF-7细胞对5氟尿嘧啶敏感性的研究[J]. 实用肿瘤学杂志, 2017, 31(5): 385-389.
[15]	罗佳宁, 郝春成, 张建鑫, 卢江岳, 葛晓峰. 术后辅助放疗对三阴性乳腺癌患者预后的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 411-416.

乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究

Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价